3 days popular7 days popular1 month popular3 months popular

Could there be a Gleevec for brain cancer?

The drug Gleevec () is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behind its development. The drug was specifically designed to target an abnormal molecule–a fusion of two normal cell proteins–that fueled a tumor’s growth.

fusion protein in tumor cells
This image shows fusion protein (red) in tumor cells from a histological section of human glioblastoma.
Credit:Lab of Antonio Iavarone


The article is titled, “Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma.” Doi:10.1158/1078-0432.CCR-14-2199

The other contributors are: , Marianne Labussiere, Karima Mokhtari, , , Blandine Boisselier, Marine Giry, , MarcSanson (Sorbonne Universités); Alessandra Fucci, Veronique Frattini, Pietro Zoppoli, Anna Lasorella (CUMC); Julien Savatovsky (); Mehdi Touat, Jean-Charles Soria (Gustave Roussy Cancer Center); Hayat Belaid, Ahmed Idbaih, Caroline Houillier (Groupe Hospitalier Pitié Salpêtrière); Feng R. Luo (Janssen Pharmaceutical); Josep Tabernero (Universitat Autònoma de Barcelona); Marica Eoli, Rosina Paterra, Gaetano Finocchiaro (Fondazione I.R.C.C.S Istituto Neurologico C. Besta); Stephen Yip (University of British Columbia); Kevin Petrecca (McGill University); and Jennifer A. Chan (University of Calgary).

The authors declare no financial or other conflicts of interest.

The study was funded by grants from the National Cancer Institute (R01CA178546), National Institute of Neurological Disorders and Stroke (R01NS061776) and a grant from The Chemotherapy Foundation.

Columbia University Medical Center